Work Here?
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Nanovation Therapeutics
Work Here?
Develops lipid nanoparticle nucleic acid therapies
Overview
NTx develops lipid nanoparticle (LNP) platforms to deliver nucleic acid therapies, including mRNA, to specific tissues. Its products are scalable, customizable LNP formulations usable across routes of administration, offered through partnerships, licensing, and direct sales to pharma companies and research institutions. The company differentiates itself with a next‑generation LNP platform and a global network of NanoVation GENErators hubs that foster international collaboration and rapid development. Its goal is to improve delivery efficiency, safety, and durability of genetic medicines to make more diseases manageable or curable.
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
Get referred to Nanovation Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- November 2024 Convergent-led funding extended runway for large-animal studies.
- April 2026 NHP results strengthen partnering leverage for immune and rare-disease programs.
- Novo’s deal spans seven programs and up to $600 million plus royalties.
What critics are saying
- NanoVation remains preclinical; no human data validates lcLNP beyond non-human primates.
- Novo controls exclusive rights on lead programs, limiting NanoVation upside and strategic freedom.
- If extrahepatic delivery disappoints, the platform becomes a niche reagent business by 2027.
What makes Nanovation Therapeutics unique
- NanoVation’s lcLNP targets extrahepatic tissues beyond liver, unlike conventional LNPs.
- Novo Nordisk licensed NanoVation’s platform in September 2024 for two lead programs.
- April 2026 NHP data showed complete B-cell depletion at 0.1 mg/kg.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$300k
Above
Industry Average
Funded Over
1 Rounds
Benefits
Health Insurance
Dental Insurance
Life Insurance
Performance Bonus
Paid Vacation
Paid Sick Leave
Company Stock Options
Professional Development Budget
Growth & Insights and Company News
6 month growth
↑ 12%1 year growth
↑ 2%2 year growth
↑ 4%Biotech is thrilled to share that NanoVation Therapeutics has been awarded the prestigious Deal of the Year award at the 27th Annual Life Sciences BC Awards!
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million to develop genetic medicines. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson and David Main, bringing extensive biotech experience.
NanoVation Therapeutics announced the expansion of its Board of Directors and the completion of a funding round led by Convergent Ventures. This follows a partnership with Novo Nordisk worth up to $600 million. The funding will advance NanoVation's lipid nanoparticle technology for RNA delivery. New board members include Zachariah Jonasson, CFO and CBO of Absci, and David Main, CEO of Notch Therapeutics, bringing expertise in biotech growth and strategic partnerships.
NanoVation Therapeutics announces expansion of Board of Directors and completion of funding round led by Convergent Ventures.
Nanovation Therapeutics partners with Novo Nordisk on genetic medicines for cardiometabolic and rare diseases.
There are no jobs for Nanovation Therapeutics right now.
Find jobs on Simplify and start your career today
About Nanovation Therapeutics
Industries
Biotechnology
Healthcare
Company Size
11-50
Company Stage
Grant
Total Funding
$300K
Headquarters
Vancouver, Canada
Founded
2020
There are no jobs for Nanovation Therapeutics right now.
Find jobs on Simplify and start your career today